Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study
Heinz Gisslinger(Medical University of Vienna), Richard Greil(Paracelsus Medical University), Michael Zoerer(AOP Orphan (Austria)), Dominik Wolf(Universität Innsbruck), Ella Willenbacher(Innsbruck Medical University), Oleh Zahriychuk(AOP Orphan (Austria)), Alexander Egle(Paracelsus Medical University), Daniel Lechner(Medical University of Vienna), Ernst Schloegl(Hanusch Hospital), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Christoph Klade(Intercell (Austria)), Bettina Gisslinger(Medical University of Vienna), Thomas Melchardt(Paracelsus Medical University), Karin Strecker(Donauspital), Josef Thaler(Thrombolysis in Myocardial Infarction Study Group), Sonja Burgstaller(Klinikum Wels-Grieskirchen), Guenther Gastl(Innsbruck Medical University), Róbert Královics(Medical University of Vienna)
Cited by 9
Related Papers
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
|New England Journal of Medicine|2005|3.5k
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Bim is a suppressor of Myc-induced mouse B cell leukemia
|Proceedings of the National Academy of Sciences|2004|482
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450